Stockhub

Tyra Biosciences, Inc.

Page Discussion
Revision as of 00:54, 27 September 2022 by 95.149.241.133 (talk) (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1]Edit

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

References and notesEdit

  1. ↑ Source: Yahoo Finance.
Retrieved from ‘https://stockhub.co/index.php?title=Tyra_Biosciences,_Inc.&oldid=77335’